Cleaved caspase-3 and nuclear factor-κB p65 are prognostic factors in metastatic serous ovarian carcinoma

Human Pathology

Volumn 40, Issue 6, 2009, Pages 795-806

  Kleinberg, Lilach ^a   Dong, Hiep Phuc ^a   Holth, Arild ^a   Risberg, Björn ^a   Trope', Claes G ^a   Nesland, Jahn M ^a   Flørenes, Vivi Ann ^a   Davidson, Ben ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Caspase; Chemotherapy; NF B; Ovarian carcinoma; Serous effusions; Survival

Indexed keywords

CASPASE 3; CASPASE 8; I KAPPA B ALPHA; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CYTOPLASM; EFFUSION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASPASE 3; CASPASE 8; CYSTADENOCARCINOMA, SEROUS; DEOXYURACIL NUCLEOTIDES; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; TRANSCRIPTION FACTOR RELA;

EID: 67349160447     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.10.019     Document Type: Article

References (52)

1. Makar A.P., Baekelandt M., Tropé C.G., and Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56 (1995) 175-180
2. Davidson B. Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog 13 (2007) 189-227
3. Nagy J.A., Masse E.M., Herzberg K.T., et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites tumor accumulation. Cancer Res 55 (1995) 360-368
4. Hirabayashi K., and Graham J. The genesis of ascites in ovarian cancer. Am J Obstet Gynecol 106 (1970) 492-497
5. Akahira J.I., Yoshikawa H., Shimizu Y., et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 81 (2001) 398-403
6. Aletti G.D., Gallenberg M.M., Cliby W.A., Jatoi A., and Hartmann L.C. Current management strategies for ovarian cancer. Mayo Clin Proc 82 (2007) 751-770
7. Rao G., Crispens M., and Rothenberg M.L. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol 25 (2007) 2867-2872
8. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
9. Agarwal R., and Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3 (2003) 502-516
10. Viktorsson K., Lewensohn R., and Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 94 (2005) 143-196
11. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
12. Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102 (2000) 1-4
13. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 15 (2001) 2922-2933
14. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55 (2005) 178-194
15. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8 (2007) 49-62
16. Schimmer A.D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64 (2004) 7183-7190
17. Liston P., Fong W.G., and Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22 (2003) 8568-8580
18. Kleinberg L., Flørenes V.A., Silins I., et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109 (2007) 228-238
19. Dong H.P., Kleinberg L., Silins I., et al. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 112 (2008) 84-93
20. Dutta J., Fan Y., Gupta N., Fan G., and Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25 (2006) 6800-6816
21. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 3 (2002) 221-227
22. Davidson B., Nielsen S., Christensen J., et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25 (2001) 1405-1412
23. Dong H.P., Kleinberg L., Davidson B., and Risberg B. Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat Protoc 3 (2008) 955-964
24. Dong H.P., Holth A., Berner A., Davidson B., and Risberg B. Flow cytometric immunphenotyping of epithelial cancer cells in effusions-technical considerations and pitfalls. Cytometry B Clin Cytom 72B (2007) 332-343
25. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
26. Havrilesky L.J., Elbendary A., Hurteau J.A., et al. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 85 (1995) 1007-1010
27. Wang T.H., Wang H.S., and Soong Y.K. Paclitaxel-induced cell death. Cancer 88 (2000) 2619-2628
28. Gibb R.K., Taylor D.D., Wan T., O'Connor D.M., Doering D.L., and Gerçel-Taylor C. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 65 (1997) 13-22
29. Davidson B., Dong H.P., Berner A., et al. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol 118 (2002) 85-92
30. Yang X., Zheng F., Xing H., et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 130 (2004) 423-428
31. Abedini M.R., Qiu Q., Yan X., and Tsang B.K. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23 (2004) 6997-7004
32. Materna V., Surowiak P., Markwitz E., et al. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep 17 (2007) 505-516
33. de Oca J., Azuara D., Sanchez-Santos R., et al. Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. Int J Colorectal Dis 23 (2008) 21-27
34. Perkins N.D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25 (2006) 6717-6730
35. Viatour P., Merville M.P., Bours V., and Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30 (2005) 43-52
36. Sakurai H., Chiba H., Miyoshi H., Sugita T., and Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274 (1999) 30353-30356
37. Sizemore N., Lerner N., Dombrowski N., Sakurai H., and Stark G.R. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 277 (2002) 3863-3869
38. Bohuslav J., Chen L.F., Kwon H., Mu Y., and Greene W.C. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279 (2004) 26115-26125
39. Sethi G., Sung B., and Aggarwal B.B. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood). 233 (2008) 21-31
40. Xiao C.W., Yan X., Li Y., Reddy S.A., and Tsang B.K. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 144 (2003) 623-630
41. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin Jr. A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
42. Tang G., Minemoto Y., Dibling B., et al. Inhibition of JNK activation through NF-kappaB target genes. Nature 414 (2001) 313-317
43. Chen C., Edelstein L.C., and Gélinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20 (2000) 2687-2695
44. Wang C.Y., Guttridge D.C., Mayo M.W., and Baldwin Jr. A.S. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19 (1999) 5923-5929
45. Chen X., Kandasamy K., and Srivastava R.K. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63 (2003) 1059-1066
46. Mabuchi S., Ohmichi M., Nishio Y., et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279 (2004) 23477-23485
47. Mabuchi S., Ohmichi M., Nishio Y., et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 10 (2004) 7645-7654
48. Izzo J.G., Malhotra U., Wu T.T., et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24 (2006) 748-754
49. Izzo J.G., Malhotra U., Wu T.T., et al. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 16 (2007) 1200-1205
50. Montagut C., Tusquets I., Ferrer B., et al. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 13 (2006) 607-616
51. Weichert W., Boehm M., Gekeler V., et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 97 (2007) 523-530
52. Zhang D., Jin X., Wang F., et al. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer. Ann Surg Oncol 14 (2007) 3581-3592